Abbott Laboratories (ABT) said Thursday it has launched a clinical trial aimed at evaluating the impact of earlier intervention using its HeartMate 3 left ventricular assist device, or heart pump, in patients with advanced heart failure.
The study, targeted to enroll up to 850 patients at 75 global sites, will use Abbott's CardioMEMS HF System sensor to monitor pulmonary artery pressures and identify patients who may benefit from early intervention with the HeartMate 3 heart pump, according to Abbott.
Abbott said enrollment will start shortly in the US. The study will assess primary and secondary endpoints after two years and continue monitoring participants for up to five years, the company added.
Price: 116.66, Change: -0.35, Percent Change: -0.30
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.